Literature DB >> 19246476

Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study.

G Alves1, B Müller, K Herlofson, I HogenEsch, W Telstad, D Aarsland, O-B Tysnes, J P Larsen.   

Abstract

OBJECTIVE: To present the incidence of Parkinson's disease (PD) in Norway and to explore gender influences on incidence and age at onset, as well as severity and pattern of parkinsonism at the time of diagnosis in a representative drug naïve cohort with newly diagnosed PD.
METHODS: In four Norwegian counties comprising a base population of 1 052 075 inhabitants, multiple sources of case ascertainment and a four step diagnostic procedure were used to establish a representative cohort of patients with incident PD at a high level of diagnostic accuracy. Of a total of 604 subjects referred to the study, 265 individuals fulfilled the clinical research criteria of PD at their latest clinical visit, at a mean 28 months after identification.
RESULTS: The incidence of PD in the study area, age standardised to the 1991 European standard population, was 12.6/10(5yr-1) (95% CI 11.1 to 14.2). The overall age standardised male to female ratio was 1.58 (95% CI 1.22 to 2.06), with a consistent male preponderance throughout all age groups. Clinical onset of PD was later in women than in men (68.6 vs 66.3 years; p = 0.062) whereas severity and pattern of parkinsonism in drug naïve patients was not different between genders at the time of diagnosis.
CONCLUSION: Incidence rates of PD in Norway are similar to those in other Western European and American countries. Female gender was associated with a considerably lower risk of PD and slightly delayed motor onset but had no impact on severity of parkinsonism or clinical phenotype in incident drug naïve PD, suggesting that the female gender influences on the nigrostriatal system are most pronounced in the preclinical phase of the disease.

Entities:  

Mesh:

Year:  2009        PMID: 19246476     DOI: 10.1136/jnnp.2008.168211

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  73 in total

Review 1.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

2.  Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment.

Authors:  Liana Apostolova; Guido Alves; Kristy S Hwang; Sona Babakchanian; Kolbjorn S Bronnick; Jan Petter Larsen; Paul M Thompson; Yi-Yu Chou; Ole B Tysnes; Hege K Vefring; Mona K Beyer
Journal:  Neurobiol Aging       Date:  2011-08-03       Impact factor: 4.673

Review 3.  Epidemiology of Parkinson's disease.

Authors:  Ole-Bjørn Tysnes; Anette Storstein
Journal:  J Neural Transm (Vienna)       Date:  2017-02-01       Impact factor: 3.575

4.  Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study.

Authors:  Corinna Vossius; Odd Bjarte Nilsen; Jan Petter Larsen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 5.  A systematic review of loss of independence in Parkinson's disease.

Authors:  Angus D Macleod; J W Kerr Grieve; Carl E Counsell
Journal:  J Neurol       Date:  2015-07-15       Impact factor: 4.849

6.  HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia.

Authors:  Charalampos Tzoulis; Tetyana Zayats; Per Morten Knappskog; Bernd Müller; Jan Petter Larsen; Ole-Bjørn Tysnes; Laurence A Bindoff; Stefan Johansson; Kristoffer Haugarvoll
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

7.  Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Bradley F Boeve; Jonathan Graff-Radford; Walter A Rocca; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

8.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

9.  A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease.

Authors:  Madeleine Kristiansen; Jodi Maple-Grødem; Guido Alves; Sampath Arepalli; Dena G Hernandez; Hirotaka Iwaki; Mike A Nalls; Andrew Singleton; Ole-Bjørn Tysnes; Mathias Toft; Lasse Pihlstrøm
Journal:  Mov Disord       Date:  2018-11-28       Impact factor: 10.338

Review 10.  From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure.

Authors:  Roberto G Lucchini; Christopher J Martin; Brent C Doney
Journal:  Neuromolecular Med       Date:  2009-12-10       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.